A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study)

Trial Profile

A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study)

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2013

At a glance

  • Drugs Telmisartan (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Acronyms INNOVATION
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 26 Feb 2010 This trial was used as evidence for an application for approval of an additional indication for type 2 diabetic incipient nephropathy, according to an Astellas Pharma media release. The application was withdrawn due to insufficient data.
    • 25 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top